Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 351–375 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
· J Clin Oncol · 2010 · PMID 20026798 · validated civic_curation pubmed
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
· Blood · 2006 · PMID 16455956 · validated civic_curation pubmed
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
· J Natl Cancer Inst · 2008 · PMID 18230792 · validated civic_curation pubmed
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
· Blood · 2004 · PMID 14726387 · validated civic_curation pubmed
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
· Nat Rev Cancer · 2007 · PMID 17891190 · validated civic_curation pubmed
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
· Cancer Res · 2001 · PMID 11585760 · validated civic_curation pubmed
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

Showing 351–375 of 736 publications

← Previous
1
…
14
15
16
…
30
Next →

· Blood · 2008 · PMID 17940205 · validated civic_curation pubmed

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

· Haematologica · 2010 · PMID 20494930 · validated civic_curation pubmed

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

· N Engl J Med · 2002 · PMID 12075054 · validated civic_curation pubmed

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

· J Clin Oncol · 2011 · PMID 21343560 · validated civic_curation pubmed

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.

· J Clin Oncol · 2012 · PMID 22430270 · validated civic_curation pubmed

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

· Blood · 2009 · PMID 19666869 · validated civic_curation pubmed

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

· J Clin Oncol · 2011 · PMID 21343549 · validated civic_curation pubmed

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

· Blood · 1997 · PMID 9207459 · validated civic_curation pubmed

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

· Blood · 2011 · PMID 21828143 · validated civic_curation pubmed

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

· Nat Genet · 2010 · PMID 20081860 · validated civic_curation pubmed

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.

· Leuk Lymphoma · 2015 · PMID 25308295 · validated civic_curation pubmed

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

· Blood · 2009 · PMID 19304957 · validated civic_curation pubmed

Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

· Blood Cancer J · 2014 · PMID 25014773 · validated civic_curation pubmed

The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.

· Genes Chromosomes Cancer · 2013 · PMID 23341344 · validated civic_curation pubmed

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.

· Leukemia · 2013 · PMID 22699455 · validated civic_curation pubmed

The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.

· Leukemia · 2006 · PMID 16307017 · validated civic_curation pubmed

Clinical and biological significance of RAS mutations in multiple myeloma.

· Leukemia · 2008 · PMID 18528420 · validated civic_curation pubmed

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

· J Clin Oncol · 2012 · PMID 22753902 · validated civic_curation pubmed

SF3B1 mutations in chronic lymphocytic leukemia.

· Blood · 2013 · PMID 23568491 · validated civic_curation pubmed